Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | STAT1 | P42224 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 3/20 | 0.56 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958735 | 0.88 | RAB9A (0.74) | RAB9APOLBTP53MAPK1NPC1 | |
| SCHEMBL3961707 | 0.80 | RAB9A (0.66) | RAB9APOLBTP53MAPK1NPC1 | |
| SCHEMBL5446413 | 0.79 | PRMT3 (0.61) | RAB9APOLBNPC1SMN1; SMN2PRMT3 | |
| SCHEMBL5449823 | 0.77 | TRPV1 (0.59) | RAB9APRMT3MTORNAMPTMEN1 | |
| SCHEMBL14470501 | 0.75 | RAB9A (0.66) | RAB9APOLBTP53MAPK1NPC1 | |
| SCHEMBL5443217 | 0.74 | PRMT3 (0.64) | RAB9APOLBNPC1PRMT3MTOR | |
| SCHEMBL4968463 | 0.73 | RAB9A (0.62) | RAB9APOLBTP53MAPK1NPC1 | |
| SCHEMBL5659561 | 0.73 | NAMPT (0.70) | PRMT3MTORNAMPTMCHR1 | |
| SCHEMBL5658162 | 0.73 | IMPDH2 (0.73) | PRMT3MTORNAMPT | |
| SCHEMBL11614113 | 0.72 | NAMPT (1.00) | MTORNAMPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078156-A1 | Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-04-05 | — | — | US | claimed |
| EP-1675587-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005028445-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-03-31 | — | — | WO | claimed |
| US-20070078156-A1 | Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-04-05 | — | — | US | disclosed |
| EP-1675587-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005028445-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078156-A1 | Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain | CNR1, OPRL1, SIGMAR1 | RAB9A 3067/4885POLB 4327/4885TP53 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.